09/28/2023
5:17 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/11/2023
5:50 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/01/2023
5:10 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/27/2023
5:05 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/12/2023
5:07 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/10/2023
5:26 AM | Sequeira Ramona (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:33 AM | Bitetti Teresa Marie (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
|
07/10/2023
5:35 AM | Takeda Pharmaceutical (Subject)
Wozniewski Thomas Otto Claus (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:16 AM | Kim Julie So-Young (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:20 AM | Duprey Lauren Rusckowski (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:22 AM | Pignagnoli Agosti Marcello (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:24 AM | Lugogo Mwana Pietrina (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:06 AM | Ricci Gabriele (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:09 AM | Plump Andrew Stewart (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:12 AM | Greco Gerard M (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023
5:14 AM | Platford Giles Richard (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/06/2023
5:18 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/03/2023
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/28/2023
5:35 AM | Takeda Pharmaceutical (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
06/28/2023
5:00 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/28/2023
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/28/2023
5:07 AM | Takeda Pharmaceutical (Filer)
| Form 20-F
Registration statement / Annual report / Transition report | |
06/23/2023
5:13 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/23/2023
5:10 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/09/2023
5:03 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/01/2023
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2023
5:19 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2023
5:20 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2023
5:11 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2023
5:14 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/26/2023
6:08 AM | Calithera Biosciences, Inc. (Issuer)
Takeda Pharmaceutical (Reporting)
Takeda Ventures, Inc. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/26/2023
6:08 AM | Calithera Biosciences, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
05/17/2023
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/15/2023
5:09 AM | Takeda Pharmaceutical (Filer)
| Form SD
Specialized Disclosure Report | |
05/11/2023
5:07 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/11/2023
5:10 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/30/2023
5:19 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/20/2023
5:17 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/16/2023
5:03 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/01/2023
5:03 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/10/2023
5:00 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
|
02/09/2023
5:00 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/07/2023
1:10 PM | BlackRock Inc. (Filed by)
Takeda Pharmaceutical (Subject)
| Form SC 13G/A | |
02/07/2023
5:05 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/03/2023
4:06 PM | Day One Biopharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13G/A | |
02/03/2023
10:50 AM | Ovid Therapeutics Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13G/A | |
02/03/2023
10:48 AM | Ovid Therapeutics Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13G/A | |
02/03/2023
5:19 AM | Sumitomo Mitsui Trust Holdings, Inc. (Filed by)
Takeda Pharmaceutical (Subject)
| Form SC 13G/A | |
02/02/2023
5:04 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/10/2023
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/05/2023
5:46 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/21/2022
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/13/2022
6:00 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/08/2022
5:46 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/01/2022
4:47 PM | HilleVax, Inc. (Issuer)
Takeda Pharmaceutical (Reporting)
Takeda Vaccines, Inc. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/30/2022
5:28 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/04/2022
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/27/2022
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/14/2022
6:36 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/04/2022
5:06 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
